Table 3 Summary of TEAEs and TRAEs in Patients Receiving ≥1 OnabotulinumtoxinA Treatment
Event, n (%) | Safety Population N = 716 |
|---|---|
TEAE | |
  ≥ 1 TEAE | 436 (60.9) |
 Serious TEAE | 75 (10.5) |
 TEAE in those that discontinued treatment | 32 (4.5) |
TRAE | |
  ≥ 1 TRAE | 131 (18.3) |
 Serious TRAE | 1 (0.1) |
 TRAE in those that discontinued treatment | 13 (1.8) |
TRAE with incidence ≥1% | |
 Neck pain | 29 (4.1) |
 Eyelid ptosis | 18 (2.5) |
 Musculoskeletal stiffness | 17 (2.4) |
 Injection site pain | 14 (2.0) |
 Headache | 12 (1.7) |
 Muscular weakness | 10 (1.4) |
 Facial paresis | 9 (1.3) |
 Migraine | 7 (1.0) |
 Skin tightness | 7 (1.0) |